Sunshine Holdings records 54% top-line growth in 1Q fuelled by acquisitions in Healthcare and Consumer

Share with your friend

  • Consolidated revenue of Rs. 7.3 billion
  • Healthcare revenue up 54% YoY to Rs.4 billion
  • Strong growth in Consumer, revenue up 68% YoY to Rs. 1.8 billion
  • Agribusiness revenue increased by 44% YoY to Rs. 1.8 billion
  • PAT increased to Rs. 1  billion, an increase of 88% YoY

Diversified Sri Lankan conglomerate Sunshine Holdings PLC (CSE: SUN) continued to demonstrate resilience amidst prevailing macro-economic conditions after reporting an impressive top-line growth of 54% YoY. The Group recorded consolidated revenue of Rs. 7.3 billion during the first quarter of the current financial year (1QFY22) and Profit after tax (PAT) grew 88% to Rs. 1 billion. The revenue increase was mainly due to impressive performances in key sectors and acquisitions in both Healthcare and Consumer over the last financial year.

The Group’s Healthcare sector emerged as the largest contributor to Sunshine’s top-line performance, accounting for 54% of total revenue, with Consumer at 25%, and Agribusiness 19% of the total revenue.

Commenting on the performance, Sunshine Group Managing Director Vish Govindasamy said, “The ongoing pandemic continues to impact every sector in the economy. For businesses in Sri Lanka, it is a test of their resilience and readiness to macro-economic challenges posed by COVID-19. However, as a Group, we are pleased to note that we displayed a resilient and entrepreneurial spirit in such difficulties, continuing our valuable contribution to the economy by ensuring undisrupted services to all our stakeholders by maintaining the highest safety standards and convenience. However, we will continue to face challenges in the short to medium term due to the negative economic impact caused by the pandemic and uncertainties in the macro environment.”


During the period in review, Group’s Healthcare sector posted revenue of Rs 4 billion during the first quarter, a significant increase of 54% YoY backed by improved performance of Sunshine Pharmaceuticals, Sunshine Medical Devices  and Healthguard Pharmacy. These business divisions results together with the contribution from the Akbar Pharmaceutical companies and Lina, the local pharmaceutical manufacturing division, resulted in the Group’s Healthcare sector PAT increasing by 58% YoY. Sunshine Healthcare Lanka was recognized as one of the Top 40 Best Workplaces in Sri Lanka by the Great Place to Work institute for the year 2021 to 2022. 


Spearheaded by brands like ‘Zesta’, ‘Watawala Tea’, ‘Ran Kahata’ and ‘Daintee’, the Consumer Goods sector reported a 68% YoY increase in revenue to close at Rs.1.8 billion. The revenue increase is mainly due to the contribution from the confectionary business segment acquired during last year. Improved performance in both tea and confectionary sub-sectors contributed to the top-line growth.


The Agribusiness sector of the Group, represented by Watawala Plantations PLC (WATA), saw a revenue increase of 44% during the first quarter compared to the same period last year. PAT of the Agri sector closed at Rs. 724 million for Q1 FY 21/22, up by Rs. 318 million compared to the same period last year, while PAT of the Dairy segment increased to Rs.18 million compared to a net loss of Rs. 4 million during the same period last year. 

About Sunshine Holdings

Sunshine Holdings PLC is a diversified conglomerate contributing to ‘nation-building’ by creating value in vital sectors of the Sri Lankan economy – healthcare, consumer products and agribusiness. Established in 1967, the Group is now home to leading Sri Lankan brands such as Zesta Tea, Watawala Tea, Ran Kahata, Daintee Confectionary and Healthguard Pharmacy, with over 2,300 employees and revenue of Rs. 24 Billion. The business units comprise of Sunshine Healthcare Lanka, Sunshine Consumer Lanka and Watawala Plantations PLC, which are leaders in their respective sectors and many of them certified as a “Great Place to Work” in 2021.

Share with your friend
Leave a Comment


No comments yet. Why don’t you start the discussion?

    Leave a Reply